ABCL (AbCellera Biologics) Growth Rank: 1 (As of Jul. 16, 2026) — 83% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ABCL AbCellera Biologics Inc ABCL
59 GF Score
Price $6.74
GF Value $5.32
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is AbCellera Biologics Growth Rank?

AbCellera Biologics ABCL 59 Growth Rank is 1 as of Jul. 16, 2026, which is 83% below its 10-year median of 6.00. GuruFocus rates ABCL with a GF Score™ of 59/100 and a GF Value™ of $5.32 (Modestly Overvalued). The stock has 3 warning signs investors should review.

AbCellera Biologics has the Growth Rank of 1.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

AbCellera Biologics Growth Rank Related Terms

ABCL vs AGIO, KOD, IMNM: Growth Rank Comparison

For the Biotechnology subindustry, AbCellera Biologics's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AbCellera Biologics Growth Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AbCellera Biologics's Growth Rank distribution charts can be found below:

* The bar in red indicates where AbCellera Biologics's Growth Rank falls into.


ABCL
59GF Score
AbCellera Biologics Inc ABCL
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 1 mean?
AbCellera Biologics (ABCL) has a Growth Rank of 1 as of Jul. 16, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on AbCellera Biologics and its competitors. This is 83% below median its historical median of 6.00. Over the past decade, AbCellera Biologics' Growth Rank has ranged from 1.00 to 9.00.
Is AbCellera Biologics' Growth Rank too high?
AbCellera Biologics' current Growth Rank of 1 is 83% below median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 9.00. Overall, AbCellera Biologics has a GF Score™ of 59/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbCellera Biologics' Growth Rank compare to AGIO and KOD?
AbCellera Biologics' Growth Rank of 1 can be compared against companies in the Biotechnology industry. Historically, AbCellera Biologics' own Growth Rank has ranged from 1.00 to 9.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Biotechnology company?
A good Growth Rank depends on the Biotechnology industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on AbCellera Biologics and its competitors. AbCellera Biologics's current Growth Rank is 1, which is 83% below median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbCellera Biologics stock overvalued right now?
Based on GuruFocus' analysis, AbCellera Biologics (ABCL) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.32, compared to a current price of $6.74 — trading 26.7% above its estimated fair value. The current Growth Rank is 1, which is 83% below median its 10-year median of 6.00. AbCellera Biologics' overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For AbCellera Biologics (ABCL), the current Growth Rank is 1 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AbCellera Biologics (ABCL) Overvalued in 2026?

Based on GuruFocus' analysis, AbCellera Biologics stock appears to be overvalued. The current stock price of $6.74 is trading 26.7% above its estimated GF Value™ of $5.32. GuruFocus considers AbCellera Biologics to be Modestly Overvalued.

Key valuation signals for ABCL:

  • Growth Rank: 1 (83% below median its 10-year median of 6.00)
  • GF Value™: $5.32 vs. price of $6.74 (26.7% above fair value)
  • GF Score™: 59/100 with 3 warning signs

No single metric tells the full story. See the ABCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AbCellera Biologics Business Description

Other Exchanges 8QQ:Germany
Address 150 W 4th Avenue, Vancouver, BC, CAN, V5Y 1G6
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
59GF Score

Get the complete analysis for ABCL

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.74
Price
$5.32
GF Value